HOUSTON, TX--(Marketwired - February 28, 2018) - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of anti...(détail)
Moleculin Biotech, Inc.
28 févr. 2018 10h05 HE
28 févr. 2018 10h05 HE
Aucun commentaire:
Enregistrer un commentaire